Get the Stockscreener App
41.34
3.02%
1.21
After Hours:
41.47
0.13
+0.31%
Rigel Pharmaceuticals stock is traded at $41.34, with a volume of 465.50K.
It is up +3.02% in the last 24 hours and up +70.54% over the past month.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$40.13
Open:
$40.31
24h Volume:
465.50K
Relative Volume:
1.03
Market Cap:
$741.53M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-295.29
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+6.41%
1M Performance:
+70.54%
6M Performance:
+103.75%
1Y Performance:
+208.28%
1-Day Range:
$39.35
$41.35
1-Week Range:
$37.97
$41.35
52-Week Range:
$12.66
$43.72
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Name
Rigel Pharmaceuticals
Sector
Industry
Phone
650-624-1100
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
41.34 | 719.83M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-23 | Resumed | Piper Sandler | Neutral |
| Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-08-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-08-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-23-22 | Initiated | B. Riley Securities | Neutral |
| Nov-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-15-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-26-19 | Resumed | JP Morgan | Overweight |
| Mar-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Aug-27-18 | Initiated | Citigroup | Buy |
| May-02-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-21-17 | Resumed | Piper Jaffray | Overweight |
| Dec-15-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-06-17 | Resumed | H.C. Wainwright | Buy |
| Mar-09-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-31-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Reiterated | Piper Jaffray | Overweight |
| Jul-13-16 | Initiated | H.C. Wainwright | Buy |
| Jun-13-16 | Initiated | Piper Jaffray | Overweight |
| Apr-22-16 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-08-13 | Reiterated | Stifel | Buy |
| Nov-29-12 | Initiated | UBS | Neutral |
| Nov-06-12 | Reiterated | Oppenheimer | Outperform |
| Mar-26-12 | Initiated | Canaccord Genuity | Hold |
| Dec-10-10 | Downgrade | MP Advisors | Outperform → Market Perform |
View All
Rigel Pharmaceuticals Stock (RIGL) Latest News
Can Rigel Pharmaceuticals Inc. continue delivering strong returnsQuarterly Profit Review & Free Long-Term Investment Growth Plans - خودرو بانک
Price momentum metrics for Rigel Pharmaceuticals Inc. explained2025 Stock Rankings & Real-Time Volume Triggers - Newser
Can Rigel Pharmaceuticals Inc. lead its sector in growth2025 Investor Takeaways & Long-Term Safe Return Strategies - خودرو بانک
Do Options Traders Know Something About RIGL Stock We Don't? - sharewise.com
What’s the MACD signal for Rigel Pharmaceuticals Inc.Trade Performance Summary & High Conviction Buy Zone Picks - خودرو بانک
Using data models to predict Rigel Pharmaceuticals Inc. stock movementMarket Activity Report & Free Daily Entry Point Trade Alerts - Newser
What earnings revisions data tells us about Rigel Pharmaceuticals Inc.Options Play & Community Consensus Picks - Newser
Will Rigel Pharmaceuticals Inc. bounce back from current supportJuly 2025 Decliners & Target Return Focused Picks - Newser
Technical analysis overview for Rigel Pharmaceuticals Inc. stockJuly 2025 Closing Moves & High Return Stock Watch Alerts - Newser
Rigel Pharmaceuticals Inc. stock prediction for this weekPortfolio Growth Summary & Advanced Swing Trade Entry Alerts - Newser
Will a bounce in Rigel Pharmaceuticals Inc. offer an exitJuly 2025 Market Mood & AI Powered Market Entry Strategies - Newser
Using R and stats models for Rigel Pharmaceuticals Inc. forecastingJuly 2025 Patterns & Daily Profit Maximizing Tips - Newser
Pattern recognition hints at Rigel Pharmaceuticals Inc. upsideJuly 2025 Gainers & Free Growth Oriented Trading Recommendations - Newser
What to expect from Rigel Pharmaceuticals Inc. in the next 30 daysWeekly Profit Report & Free Daily Entry Point Trade Alerts - Newser
Analyzing recovery setups for Rigel Pharmaceuticals Inc. investorsEarnings Risk Report & AI Enhanced Trading Alerts - Newser
What are Rigel Pharmaceuticals Inc.’s recent SEC filings showingEarnings Trend Report & Weekly Stock Performance Updates - خودرو بانک
Is Rigel Pharmaceuticals Inc.’s growth already priced inTrade Entry Report & Expert-Curated Trade Recommendations - خودرو بانک
Historical volatility pattern of Rigel Pharmaceuticals Inc. visualizedGap Up & Weekly Setup with High ROI Potential - Newser
Developing predictive dashboards with Rigel Pharmaceuticals Inc. dataAnalyst Upgrade & Accurate Intraday Trade Tips - Newser
Can technical indicators confirm Rigel Pharmaceuticals Inc.’s reversalWatch List & Safe Entry Point Identification - Newser
Tools to monitor Rigel Pharmaceuticals Inc. recovery probabilityWeekly Investment Recap & Free Growth Oriented Trading Recommendations - Newser
Sector ETF performance correlation with Rigel Pharmaceuticals Inc.July 2025 Institutional & Fast Entry and Exit Trade Plans - Newser
Automated trading signals detected on Rigel Pharmaceuticals Inc.Quarterly Growth Report & Daily Entry Point Alerts - Newser
Is Rigel Pharmaceuticals Inc. a candidate for recovery playOil Prices & Real-Time Stock Entry Alerts - Newser
Rigel Pharmaceuticals at Cantor Conference: Strategic Growth and Expansion - Investing.com
Will Rigel Pharmaceuticals Inc. continue its uptrendSwing Trade & Expert Verified Stock Movement Alerts - Newser
Does Rigel Pharmaceuticals (NASDAQ:RIGL) Have A Healthy Balance Sheet? - simplywall.st
Smart tools for monitoring Rigel Pharmaceuticals Inc.’s price actionJuly 2025 Action & Fast Entry and Exit Trade Plans - Newser
Rigel Pharmaceuticals Inc. stock outlook for YEARWeekly Profit Recap & Verified Trade Idea Suggestions - Newser
Multi asset correlation models including Rigel Pharmaceuticals Inc.Trend Reversal & Reliable Entry Point Trade Alerts - Newser
What is Rigel Pharmaceuticals Inc. s debt to equity ratioWeekly Stock Recap & Community Shared Stock Ideas - خودرو بانک
Can Rigel Pharmaceuticals Inc. navigate macro headwindsQuarterly Portfolio Report & Verified Entry Point Signals - خودرو بانک
Backtesting results for Rigel Pharmaceuticals Inc. trading strategiesTrade Volume Report & Long-Term Safe Investment Ideas - Newser
Will Rigel Pharmaceuticals Inc. Reverse From Oversold ConditionsJuly 2025 Institutional & Capital Protection Trading Alerts - beatles.ru
Rigel Pharmaceuticals shares fall 1.13% premarket after DelveInsight's report on TGFB Inhibitor pipeline. - AInvest
Why is Rigel Pharmaceuticals Inc. stock going downMarket Sentiment Review & Precise Trade Entry Recommendations - خودرو بانک
Evaluating Rigel Pharmaceuticals Inc. with trendline analysisJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - Newser
Rigel Pharmaceuticals Stock (RIGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):